ANI Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
Company: ANI Pharmaceuticals, Inc.
Filing Date: September 26, 2025
Reporting Period: Current report covering events on August 14, 2025, and September 26, 2025.
Event: Mandatory and optional conversion of all outstanding Series A Convertible Preferred Stock into Common Stock.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes.
| Metric | Value |
|---|---|
| Preferred Shares Converted | 25,000 (Total) |
| Common Shares Issued | 602,900 (Aggregate) |
| Conversion Price | $41.4662 per Common Share |
| Remaining Preferred Shares | 0 |
Material Changes
- Capital Structure: The Company eliminated all outstanding Series A Convertible Preferred Stock. Previously, 25,000 shares were issued in 2021 to Ampersand 2020 Limited Partnership for $25 million.
- Conversion Events:
- August 14, 2025: Ampersand voluntarily converted 5,000 Preferred Shares into 120,580 Common Shares.
- September 26, 2025: The Company mandatorily converted the remaining 20,000 Preferred Shares into 482,320 Common Shares.
- Trigger Condition: The mandatory conversion was triggered because the volume-weighted average price of the Common Stock exceeded 170% of the conversion price for 20 out of 30 consecutive trading days following the second anniversary of issuance.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the completion of the conversion process in accordance with the Certificate of Designation. No forward-looking guidance or outlook is provided in this document.
Risks and Contingencies: The issuance of Common Shares was made in reliance on the Section 3(a)(9) exemption from registration under the Securities Act of 1933, as it involved an exchange exclusively with an existing security holder without commission.
Investor Verification Checklist
- Verify the exact number of Common Shares issued (602,900) and the resulting dilution impact on existing shareholders.
- Confirm the current volume-weighted average price of ANIP stock to validate the 170% trigger condition cited for mandatory conversion.
- Review the original Certificate of Designation (Exhibit 3.1 from the November 26, 2021 filing) for any remaining dividend obligations or rights associated with the converted shares.
- Check subsequent filings for any changes in the Company's authorized share count or treasury stock levels.